These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 27362900)

  • 1. The Prognostic Value of BRCA1 and PARP Expression in Epithelial Ovarian Carcinoma: Immunohistochemical Detection.
    Hjortkjær M; Waldstrøm M; Jakobsen A; Kanstrup H; Søgaard-Andersen E; Dahl Steffensen K
    Int J Gynecol Pathol; 2017 Mar; 36(2):180-189. PubMed ID: 27362900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival.
    Gan A; Green AR; Nolan CC; Martin S; Deen S
    Hum Pathol; 2013 Aug; 44(8):1638-47. PubMed ID: 23574784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of poly (adenosine diphosphate-ribose) polymerase and p53 in epithelial ovarian cancer and their role in prognosis and disease outcome.
    Godoy H; Mhawech-Fauceglia P; Beck A; Miller A; Lele S; Odunsi K
    Int J Gynecol Pathol; 2011 Mar; 30(2):139-44. PubMed ID: 21293287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer.
    Hjortkjær M; Malik Aagaard Jørgensen M; Waldstrøm M; Ørnskov D; Søgaard-Andersen E; Jakobsen A; Dahl-Steffensen K
    Int J Gynecol Cancer; 2019 Jan; 29(1):166-173. PubMed ID: 30640700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCAness profile of sporadic ovarian cancer predicts disease recurrence.
    Wysham WZ; Mhawech-Fauceglia P; Li H; Hays L; Syriac S; Skrepnik T; Wright J; Pande N; Hoatlin M; Pejovic T
    PLoS One; 2012; 7(1):e30042. PubMed ID: 22253870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDKN3 is an independent prognostic factor and promotes ovarian carcinoma cell proliferation in ovarian cancer.
    Li T; Xue H; Guo Y; Guo K
    Oncol Rep; 2014 Apr; 31(4):1825-31. PubMed ID: 24573179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated expression of MAC30 predicts lymph node metastasis and unfavorable prognosis in patients with epithelial ovarian cancer.
    Yang S; Li H; Liu Y; Ning X; Meng F; Xiao M; Wang D; Lou G; Zhang Y
    Med Oncol; 2013 Mar; 30(1):324. PubMed ID: 23254963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Young Israeli women with epithelial ovarian cancer: prevalence of BRCA mutations and clinical correlates.
    Helpman L; Zidan O; Friedman E; Kalfon S; Perri T; Ben-Baruch G; Korach J
    J Gynecol Oncol; 2017 Sep; 28(5):e61. PubMed ID: 28657222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of ASAP1 is associated with poor prognosis in epithelial ovarian cancer.
    Hou T; Yang C; Tong C; Zhang H; Xiao J; Li J
    Int J Clin Exp Pathol; 2014; 7(1):280-7. PubMed ID: 24427349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulation of Abelson interactor protein 1 predicts tumor progression and poor outcome in epithelial ovarian cancer.
    Zhang J; Tang L; Chen Y; Duan Z; Xiao L; Li W; Liu X; Shen L
    Hum Pathol; 2015 Sep; 46(9):1331-40. PubMed ID: 26193797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of phosphorylated Akt and hTERT is associated with prognosis of epithelial ovarian carcinoma.
    Lee YK; Chung HH; Kim JW; Song YS; Park NH
    Int J Clin Exp Pathol; 2015; 8(11):14971-6. PubMed ID: 26823830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
    Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
    Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of MNK1 in prognostic prediction and chemotherapy development of epithelial ovarian cancer.
    Hou S; Du P; Wang P; Wang C; Liu P; Liu H
    Clin Transl Oncol; 2017 Sep; 19(9):1107-1116. PubMed ID: 28332091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis.
    Sun C; Li N; Ding D; Weng D; Meng L; Chen G; Ma D
    PLoS One; 2014; 9(5):e95285. PubMed ID: 24788697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and clinical significance of cortactin protein in ovarian neoplasms.
    Li A; Zhang L; Zhang X; Jin W; Ren Y
    Clin Transl Oncol; 2016 Feb; 18(2):220-7. PubMed ID: 26243395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No association between BRCA1 immunohistochemical expression and tumor grade, stage or overall survival in platinum-treated epithelial ovarian cancer patients.
    Shawky Ael-A; El-Hafez AA; El-Tantawy D; Hamdy R
    Asian Pac J Cancer Prev; 2014; 15(10):4275-9. PubMed ID: 24935384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of Siah2 Is Associated With Poor Prognosis in Patients With Epithelial Ovarian Carcinoma.
    Gao Y; Liu Y; Meng F; Shang P; Wang S; Zhang Y; Sun Y; Wang Y; Wang J; Chen X
    Int J Gynecol Cancer; 2016 Jan; 26(1):114-9. PubMed ID: 26512788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of PARP protein expression in epithelial ovarian cancer by ELISA pharmacodynamic assay and immunohistochemistry.
    Veskimäe K; Staff S; Grönholm A; Pesu M; Laaksonen M; Nykter M; Isola J; Mäenpää J
    Tumour Biol; 2016 Sep; 37(9):11991-11999. PubMed ID: 27155850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impact of high mobility group box 1 protein in epithelial ovarian cancer.
    Paek J; Lee M; Nam EJ; Kim SW; Kim YT
    Arch Gynecol Obstet; 2016 Mar; 293(3):645-50. PubMed ID: 26305032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.